StreetAlpha.app
Home › Stocks › DFTX

Definium Therapeutics, Inc. (DFTX)

Healthcare
$29.38
▼ −2.59%
LAST CLOSE · NOV 17

Definium Therapeutics develops treatments based on psychedelic compounds for brain health disorders such as anxiety, depression and autism. It last closed at $29.38 on Nov 17, down 2.59% on the day. DFTX last reported earnings on Mon, Nov 9, 2026. The average 12-month price target from 5 analysts is $75.60 (+157.3% from the last close), with a high of $85.00 and a low of $66.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in DFTX, 50% of them bullish and 50% bearish.

AI Auto Pilots
Is DFTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$337.5M
EPS (diluted)
−$2.92
Valuation
Market cap
$4.0B
136.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$241.2M
At Sep 30
Debt
$36.7M
At Sep 30
Shareholder equity
$968.0M
Shares outstanding
136.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$93.0M−$93.0MFY2021FY2022: −$56.8M−$56.8MFY2022FY2023: −$95.7M−$95.7MFY2023FY2024: −$108.7M−$108.7MFY2024FY2025: −$183.8M−$183.8MFY2025

From DFTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · After the close (AMC)
Reported EPS
-$0.46
vs -$0.55 est. · beat
Year-ago EPS
-$0.78
Same quarter last year
Options-implied move
±11.3%
Priced in before that report
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on DFTX in the past 90 days
Average 12-month target
$75.60
▲ 157.3% upside

Based on 5 analysts who set a price target on DFTX in the past 90 days. The average target is $75.60, with a high of $85.00 and a low of $66.00, compared with the last close of $29.38.

$20$43$67$90PAST 15 TRADING DAYS12-MONTH TARGETSHIGH $85AVG $75.60LOW $66Jun 12LAST CLOSE+12 MO$20$43$67$90PAST 15 DAYSTARGETSHIGH $85AVG $75.60LOW $66Jun 12LAST CLOSE+12 MO
Highest target$85.00
Average target$75.60
Lowest target$66.00
Latest rating changes
JP MorganMaintained
Nov 17Buy$85
RBC CapitalTarget raised
Nov 10Buy$66 → $70
JP MorganInitiated
Oct 9Buy$84
Canaccord GenuityTarget raised
Sep 15Buy$64 → $78
BairdTarget raised
Sep 15Buy$75 → $79
DateFirmActionRatingPrice target
Nov 17JP MorganMaintainedBuy$85
Nov 10RBC CapitalTarget raisedBuy$66 → $70
Oct 9JP MorganInitiatedBuy$84
Sep 15Canaccord GenuityTarget raisedBuy$64 → $78
Sep 15BairdTarget raisedBuy$75 → $79
Loading…

Technical Analysis

DFTX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 16% below its 20 day and 22% below its 50 day average. It is 4% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $28.38, and the nearest resistance the Pivot at $29.45.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.1%/day
Key levels
$49.7052 week high+69.2%
$39.65100 day average+35.0%
$35.97Swing high (Nov 10)+22.4%
$35.7350 day average+21.6%
$34.1620 day average+16.3%
$30.55200 day average+4.0%
$30.45Pivot R1+3.6%
$29.45Pivot+0.2%
$29.38Last close
$28.38Pivot S1−3.4%
$22.15Swing low (Jun 2)−24.6%
$10.4652 week low−64.4%
Indicators
RSI (14)35.77Weak, oversold below 30Neutral
MACD-1.34Below its signal lineBearish
Stochastic10.4Near the bottom of its rangeOversold
ADX (14)17.5No clear trend
Williams %R-91.3Oversold below −80, overbought above −20Oversold
CCI (20)-166.1Oversold below −100, overbought above 100Oversold
Rate of change−12.1%Change over 10 sessionsBearish
ATR (14)$2.07Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DFTX

What happened before

See how DFTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed2 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow DFTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DFTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
4
Bullish
2
50%
Bearish
2
50%
Date span
Sep 3 – Oct 1
Loading…

See today’s whale options flow across the market →

DFTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲199 buying vs 167 selling
  • ▲Held by funds +2.2 pts
  • ▼Funds holding -9
  • ▼Superinvestors: 0 added, 4 cut
  • ▲Put/call 0.22 to 0.19
Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding354363−2.5%
In funds' top 101013−23.1%
Held by funds86.1%84.0%+2.2 pts
New / increased62 / 137144 / 116−23.5%
Reduced / sold out97 / 7064 / 30+77.7%
Put/call ratio0.190.22−12.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DFTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DFTX is in one of them and how their past DFTX trades turned out.

DFTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DFTX in an article yet. Here's the latest on the wider market.

About Definium Therapeutics

Definium Therapeutics is a drug developer based in New York that is working on treatments for brain health conditions. Its main product candidates are derived from psychedelic and empathogen compounds. The lead candidate, DT120, is being tested in adults with generalized anxiety disorder and major depressive disorder, and a second candidate, DT402, is being studied in adults with autism spectrum disorder. None of its products are approved for sale yet, and the company is aiming to offer them to patients under medical care.

Headquarters
New York, NY